Consolidated Statement of Comprehensive Income
Show table
€ million | Note | 2014 | 2013 |
---|---|---|---|
Profit after tax | 1,164.8 | 1,209.1 | |
Items of other comprehensive income that will not be reclassified to profit or loss in subsequent periods: | |||
Remeasurement of the net defined benefit liability | |||
Changes in remeasurement | → 49 | – 861.5 | 98.8 |
Tax effect | → 32 | 149.2 | – 16.3 |
Changes recognized in equity | – 712.3 | 82.5 | |
– 712.3 | 82.5 | ||
Items of other comprehensive income that may be reclassified to profit or loss in subsequent periods: | |||
Available-for-sale financial assets | |||
Fair value adjustments | – 1.4 | 1.8 | |
Reclassification to profit or loss | – 0.1 | – 1.6 | |
Tax effect | → 32 | 0.4 | – 0.4 |
Changes recognized in equity | – 1.1 | – 0.2 | |
Derivative financial instruments | |||
Fair value adjustments | 411.7 | 125.5 | |
Reclassification to profit or loss | – 43.0 | – 26.5 | |
Reclassification to assets | – | – | |
Tax effect | → 32 | – 20.2 | – 25.3 |
Changes recognized in equity | 348.5 | 73.7 | |
Exchange differences on translating foreign operations | |||
Changes taken directly to equity | 682.4 | – 204.9 | |
Reclassification to profit or loss | 0.1 | – 8.9 | |
Changes recognized in equity | 682.5 | – 213.8 | |
1,029.9 | – 140.3 | ||
Other comprehensive income | 317.6 | – 57.8 | |
Comprehensive income | 1,482.4 | 1,151.3 | |
of which attributable to Merck KGaA shareholders | 1,469.1 | 1,154.6 | |
of which attributable to non-controlling interests | → 33 | 13.3 | – 3.3 |